Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HG Capital Leads $23 Million Round in Nuokangda Pharma

publication date: Feb 14, 2017
HG Capital, a Beijing-based private equity firm, led a $23 million investment in Beijing Nuokangda Pharmaceutical Technology, a CRO company focused on innovative medicine, supplements and medical equipment. Nuokangda plans to use the proceeds to prepare for an IPO on a domestic stock exchange in the near future. Beijing-based K2 Venture Capital, the investment unit of Chinese investment banking firm China Renaissance Partners, also participated. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital